Show Summary Details
- Dedication
- Foreword
- Preface
- Acknowledgements
- Abbreviations
- Contributor List
- Chapter 1 Adaptive T-cell immunity and tumor antigen recognition
- Chapter 2 Impact of ageing and body mass on cancer immunotherapy outcomes
- Chapter 3 The potential of natural killer cells in cancer immunotherapy
- Chapter 4 The tumor microenvironment: The role of tumor-associated macrophages in cancer progression and responses to therapy
- Chapter 5 ‘Hard’ and ‘soft’ loss of MHC class I expression in cancer cells
- Chapter 6 Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses
- Chapter 7 Myeloid-derived suppressor cells: Immune-suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation
- Chapter 8 Triggering death receptors to promote cancer cell death
- Chapter 9 Identification of tumor antigens for clinical evaluation
- Chapter 10 Viral antigens as targets for prophylactic and therapeutic intervention in cancer
- Chapter 11 HER2/neu as a target for vaccine and antibody-directed therapies
- Chapter 12 Pre-clinical evaluation of immunotherapy: The case for prostate cancer and the TRAMP model
- Chapter 13 Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy
- Chapter 14 Predictive biomarkers to better select patients for cancer immunotherapy
- Chapter 15 Viral platforms for expression of tumor antigens in cancer immunotherapy
- Chapter 16 Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies
- Chapter 17 DNA vaccines
- Chapter 18 Programming the immune system through childhood infections: MUC1 tumor-associated antigen (TAA) as a disease-associated antigen (DAA)
- Chapter 19 Vaccination against myeloid leukaemias using newly defined antigens
- Chapter 20 Immune-checkpoint blockade in cancer immunotherapy
- Chapter 21 Multi-peptide cancer vaccines for clinical application
- Chapter 22 Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma
- Chapter 23 Chimeric antigen receptor gene therapy in cancer
- Chapter 24 The vaccinal effect of monoclonal antibodies in cancer therapy
- Chapter 25 Antibody therapies: defining appropriate cell surface epitopes for targeting tumors
- Chapter 26 Adoptive lymphocyte (stem cell) therapy in cancer
- Chapter 27 Cancer stem cells (CSCs) and epithelial-to-mesenchymal transition (EMT): Tumor cell plasticity challenges immunotherapy
- Chapter 28 Immune escape and ageing of the immune system compromises the immune response to tumor antigens
- Index
(p. xxi) Contributor List
(p. xxi)
Contributor List
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- Dedication
- Foreword
- Preface
- Acknowledgements
- Abbreviations
- Contributor List
- Chapter 1 Adaptive T-cell immunity and tumor antigen recognition
- Chapter 2 Impact of ageing and body mass on cancer immunotherapy outcomes
- Chapter 3 The potential of natural killer cells in cancer immunotherapy
- Chapter 4 The tumor microenvironment: The role of tumor-associated macrophages in cancer progression and responses to therapy
- Chapter 5 ‘Hard’ and ‘soft’ loss of MHC class I expression in cancer cells
- Chapter 6 Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses
- Chapter 7 Myeloid-derived suppressor cells: Immune-suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation
- Chapter 8 Triggering death receptors to promote cancer cell death
- Chapter 9 Identification of tumor antigens for clinical evaluation
- Chapter 10 Viral antigens as targets for prophylactic and therapeutic intervention in cancer
- Chapter 11 HER2/neu as a target for vaccine and antibody-directed therapies
- Chapter 12 Pre-clinical evaluation of immunotherapy: The case for prostate cancer and the TRAMP model
- Chapter 13 Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy
- Chapter 14 Predictive biomarkers to better select patients for cancer immunotherapy
- Chapter 15 Viral platforms for expression of tumor antigens in cancer immunotherapy
- Chapter 16 Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies
- Chapter 17 DNA vaccines
- Chapter 18 Programming the immune system through childhood infections: MUC1 tumor-associated antigen (TAA) as a disease-associated antigen (DAA)
- Chapter 19 Vaccination against myeloid leukaemias using newly defined antigens
- Chapter 20 Immune-checkpoint blockade in cancer immunotherapy
- Chapter 21 Multi-peptide cancer vaccines for clinical application
- Chapter 22 Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma
- Chapter 23 Chimeric antigen receptor gene therapy in cancer
- Chapter 24 The vaccinal effect of monoclonal antibodies in cancer therapy
- Chapter 25 Antibody therapies: defining appropriate cell surface epitopes for targeting tumors
- Chapter 26 Adoptive lymphocyte (stem cell) therapy in cancer
- Chapter 27 Cancer stem cells (CSCs) and epithelial-to-mesenchymal transition (EMT): Tumor cell plasticity challenges immunotherapy
- Chapter 28 Immune escape and ageing of the immune system compromises the immune response to tumor antigens
- Index